26-07-2024 |
PM |
|
BMY |
Bristol-Myers Squibb Company |
90,530 |
2.07 |
1.64 |
1.75 |
Bristol-Myers Squibb Company Non-GAAP EPS of $2.07 beats by $0.44, revenue of $12.2B beats by $680M [7/26/2024 7:00 AM] |
50.42 |
5.15 (11.39%) |
48.13 |
2.86 (6.32%) |
39.35 - 63.89 |
28,773,161 |
16,940,000 |
1,523,441 |
|
|
25-04-2024 |
PM |
|
BMY |
Bristol-Myers Squibb Company |
99,070 |
1.90 |
1.53 |
2.05 |
Bristol-Myers Squibb Company Non-GAAP EPS of -$4.40 beats by $0.02, revenue of $11.78B beats by $330M [4/25/2024 7:01 AM] |
44.74 |
-4.12 (-8.43%) |
47.50 |
-1.36 (-2.78%) |
44.37 - 70.93 |
40,661,824 |
11,420,000 |
267,928 |
|
|
02-02-2024 |
PM |
|
BMY |
Bristol-Myers Squibb Company |
99,440 |
1.70 |
1.52 |
1.82 |
Bristol-Myers Squibb beats top-line and bottom-line estimates; initiates FY24 outlook [2/2/2024 7:01 AM] |
48.73 |
0.06 (0.12%) |
49.25 |
0.58 (1.19%) |
48.08 - 75.18 |
20,776,985 |
15,280,000 |
1,767,605 |
|
|
26-10-2023 |
PM |
|
BMY |
Bristol-Myers Squibb Company |
117,240 |
2.00 |
1.76 |
1.99 |
Bristol-Myers Squibb Company Non-GAAP EPS of $2.00 beats by $0.23, revenue of $10.97B in-line [10/26/2023 7:03 AM] |
53.01 |
-3.60 (-6.37%) |
53.82 |
-2.79 (-4.93%) |
52.98 - 81.43 |
20,835,611 |
11,700,000 |
1,099,419 |
|
|
27-07-2023 |
PM |
|
BMY |
Bristol-Myers Squibb Company |
135,990 |
1.75 |
2.00 |
1.93 |
Bristol-Myers Squibb Company Non-GAAP EPS of $1.75 misses by $0.24, revenue of $11.2B misses by $610M [7/27/2023 7:00 AM] |
60.76 |
-2.65 (-4.18%) |
60.81 |
-2.60 (-4.10%) |
60.38 - 81.43 |
18,678,296 |
8,490,000 |
968,672 |
|
|
27-04-2023 |
PM |
7:00 AM ET (Apr 27) |
BMY |
Bristol-Myers Squibb Company |
147,740 |
2.05 |
1.98 |
1.96 |
Bristol-Myers Squibb Company Non-GAAP EPS of $2.05 beats by $0.05, revenue of $11.3B misses by $290M [4/27/2023 7:33 AM] |
67.58 |
-0.44 (-0.64%) |
67.94 |
-0.08 (-0.12%) |
65.28 - 81.43 |
8,604,214 |
6,400,000 |
40,423 |
|
|
02-02-2023 |
PM |
7:00 AM ET (Feb 2) |
BMY |
Bristol-Myers Squibb Company |
153,150 |
1.82 |
1.71 |
1.83 |
Bristol-Myers Squibb Company Non-GAAP EPS of $1.82 beats by $0.09, revenue of $11.4B beats by $200M [2/2/2023 7:00 AM] |
72.81 |
1.58 (2.22%) |
71.75 |
0.52 (0.73%) |
62.90 - 81.43 |
9,966,219 |
8,220,000 |
53,544 |
|
|
25-10-2022 |
PM |
7:00 AM ET (Oct 26) |
BMY |
Bristol-Myers Squibb Company |
155,850 |
1.99 |
1.83 |
2.00 |
Bristol Myers Squibb Non-GAAP EPS of $1.99 beats by $0.16, revenue of $11.22B beats by $40M, re-affirms FY22 outlook [10/26/2022 3:17 AM] |
74.41 |
1.64 (2.25%) |
72.50 |
-0.27 (-0.37%) |
53.22 - 80.59 |
8,197,383 |
8,000,000 |
60,499 |
|
|
27-07-2022 |
PM |
7:00 AM ET (Jul 27) |
BMY |
Bristol-Myers Squibb Company |
155,320 |
1.93 |
1.79 |
1.93 |
Bristol Myers Squibb Non-GAAP EPS of $1.93 beats by $0.12, revenue of $11.9B beats by $400M, cuts FY22 outlook [7/27/2022 7:02 AM] |
74.72 |
1.09 (1.48%) |
72.20 |
-1.43 (-1.94%) |
53.22 - 80.59 |
7,464,561 |
9,070,000 |
84,450 |
|
|
29-04-2022 |
PM |
7:00 AM ET (Apr 29) |
BMY |
Bristol-Myers Squibb Company |
161,110 |
1.96 |
1.92 |
1.74 |
Bristol Myers Squibb Non-GAAP EPS of $1.96 beats by $0.07, revenue of $11.6B beats by $260M [4/29/2022 7:01 AM] |
75.29 |
-1.91 (-2.47%) |
73.50 |
-3.70 (-4.79%) |
53.22 - 78.17 |
22,866,356 |
13,990,000 |
163,078 |
|
-
Will Bristol Myers Squibb positive earnings momentum continue in Q1? [4/28/2022 11:54 AM]
-
Bristol Myers Squibb Non-GAAP EPS of $1.96 beats by $0.07, revenue of $11.6B beats by $260M [4/29/2022 7:01 AM]
-
Bristol Myers stock dips despite Q1 beat, as FY22 EPS outlook trimmed, Revlimid to see decline [4/29/2022 8:06 AM]
-
Bristol Myers, LianBio win FDA approval for Camzyos to treat heart disorder [4/29/2022 6:24 AM]
-
Dow Jones Futures: Market Rebounds, But For How Long? Apple, Amazon Hit Techs [Apr-28-22 08:56PM]
-
U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms [Apr-28-22 08:01PM]
-
Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN [Apr-28-22 10:53AM]
-
Why Bristol-Myers (BMY) Might Surprise This Earnings Season [Apr-28-22 08:40AM]
-
UPDATE 1-FDA approves Bristol Myers' heart disease drug [Apr-28-22 09:06PM]
-
Dow Jones Futures: Apple, Amazon Hit Techs After Market Rebound; Elon Musk Sells Tesla Stock [Apr-28-22 10:10PM]
-
UPDATE 2-FDA approves Bristol Myers' oral heart disease drug [Apr-28-22 09:06PM]
-
Dow Jones Futures Fall On Apple, Amazon After Market Rebound; Tesla Rises On Elon Musk Move [Apr-29-22 06:43AM]
-
Bristol Myers Squibb Reports First Quarter Financial Results for 2022 [Apr-29-22 06:59AM]
-
Bristol Myers 1st-quarter sales up on Eliquis, Opdivo [Apr-29-22 07:04AM]
-
Bristol Myer Squibb's stock falls after cutting adjusted EPS for 2022 [Apr-29-22 07:32AM]
-
Bristol Myers Squibb Dives As Generics, Revlimid Rivals Slam 2022 Outlook [Apr-29-22 08:49AM]
-
R&D Facility Building in the UK Exemplifies Sustainability Innovation [Apr-29-22 09:04AM]
-
Bristol Myers Takes Machete To 2022 Outlook As Generics Slam Revlimid, Abraxane [Apr-29-22 09:33AM]
-
Dow Jones Falls, Techs Slide After Market Rebound; Tesla Rises On Elon Musk Move [Apr-29-22 09:49AM]
-
Dow Jones Well Off Lows As Apple Rises; Tesla Jumps On Elon Musk Move [Apr-29-22 10:02AM]
-
Bristol Myers Squibb (BMY) Q1 Earnings and Revenues Surpass Estimates [Apr-29-22 08:15AM]
-
Dow Jones Off Lows As Apple Rises; Tesla Jumps On Elon Musk Move [Apr-29-22 10:15AM]
-
Dow Jones Falls, Nasdaq Skids On Amazon, AbbVie; Tesla Rises On Elon Musk Move [Apr-29-22 10:43AM]
-
Amazon, Robinhood Slump in Premarket; Apple, Exxon, Bristol Myers-Squibb Fall [Apr-29-22 04:48AM]
-
Bristol Myers Q1 Earnings Surpass Street Expectations, Lowers FY22 Guidance [Apr-29-22 08:09AM]
-
FDA OKs heart drug at center of $13 billion deal for Peninsula company [Apr-29-22 11:12AM]
-
PCE +6.6%, Another 40-Year High; XOM, CL, BMY Report [Apr-29-22 10:40AM]
-
Core PCE Inflation at a 40-Year High in March [Apr-29-22 11:19AM]
-
Bristol Myers Squibb (BMY) Q1 2022 Earnings Call Transcript [Apr-29-22 02:00PM]
-
Bristol-Myers (BMY) Q1 Earnings Beat Estimates, Guidance Down [Apr-29-22 12:29PM]
|
04-02-2022 |
PM |
7:00 AM ET (Feb 4) |
BMY |
Bristol-Myers Squibb Company |
143,830 |
1.83 |
1.83 |
1.46 |
Bristol Myers Squibb Non-GAAP EPS of $1.83 beats by $0.03, revenue of $12B in-line [2/4/2022 7:00 AM] |
65.00 |
0.93 (1.45%) |
63.10 |
-0.97 (-1.51%) |
53.22 - 69.75 |
10,652,060 |
13,910,000 |
190,279 |
|
-
Can Bristol Myers (BMY) maintain positive earnings momentum in Q4? [2/3/2022 7:13 AM]
-
Bristol Myers Squibb Non-GAAP EPS of $1.83 beats by $0.03, revenue of $12B in-line [2/4/2022 7:00 AM]
-
Bristol-Myers sets 2022 guidance ahead of consensus after earnings beat [2/4/2022 7:32 AM]
-
Garnet Equity Capital Holdings, Inc. Buys Flex, Hertz Global Holdings Inc, Universal Display ... [Feb-03-22 09:38PM]
-
Bristol Myers posts slightly better-than-expected 4th-qtr results [Feb-04-22 07:00AM]
-
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021 [Feb-04-22 06:59AM]
-
Bristol-Myers Stock Gains As Opdivo, Eliquis Sales Drive Q4 Earnings Beat [Feb-04-22 02:18AM]
-
Bristol's stock gains after beating earnings estimates for the fourth quarter [Feb-04-22 07:29AM]
-
Dow Jones Futures Fall Ahead Of Jobs Report; Amazon Soars, But Ford Dives On Earnings [Feb-04-22 08:08AM]
-
Dow Jones Futures Slide On Jobs Report; Amazon Soars, But Ford Dives On Earnings [Feb-04-22 08:35AM]
-
Dow Jones Futures Slide As Yields Surge On Jobs Report; Amazon Soars, But Ford Dives On Earnings [Feb-04-22 08:37AM]
-
ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021 [Feb-04-22 08:49AM]
-
Bristol Myers Ekes Out Earnings Beat As Cancer Drugs Spur Growth [Feb-04-22 09:14AM]
-
Dow Jones Falls As Yields Surge On Jobs Report; Amazon Soars, But Ford Dives On Earnings [Feb-04-22 09:32AM]
-
Oak Asset Management, LLC Buys Science Applications International Corp, Merck Inc, ... [Feb-04-22 09:38AM]
-
Bristol Myers Squibb (BMY) Q4 Earnings Meet Estimates [Feb-04-22 08:25AM]
-
Amazon, Snap, Pinterest Rise Premarket; Ford, Clorox Fall [Feb-04-22 02:58AM]
-
Stock Market Reverses Higher After Hot Jobs Report, Amazon Earnings [Feb-04-22 10:14AM]
-
Bristol Myers Expects $10.5 Billion Shortfall This Year As Generics Loom [Feb-04-22 11:05AM]
-
Stocks Trade Mixed On Strong Jobs Report; Amazon Gains On Solid Earnings [Feb-04-22 12:23PM]
-
Stocks Drop as Jobs Report Increases Rate-Hike Jitters [Feb-04-22 12:05PM]
-
Bristol-Myers (BMY) Q4 Earnings Meet Estimates, Sales Beat [Feb-04-22 11:45AM]
-
Ruffer LLP Buys Kinross Gold Corp, Barrick Gold Corp, Hertz Global Holdings Inc, Sells Centene ... [Feb-04-22 01:38PM]
-
Pictet North America Advisors SA Buys Fidelity National Information Services Inc, Johnson ... [Feb-04-22 01:38PM]
-
Amazon, Snap Fuel Tech; Dow Drops on Rate Worries [Feb-04-22 02:19PM]
|
27-10-2021 |
PM |
7:00 AM ET (Oct 27) |
BMY |
Bristol-Myers Squibb Company |
127,990 |
2.00 |
1.91 |
1.63 |
Bristol Myers Squibb EPS beats by $0.08, beats on revenue, boost guidance [10/27/2021 7:02 AM] |
56.49 |
-1.75 (-3.00%) |
56.49 |
0.0 (0.00%) |
56.11 - 69.75 |
18,450,664 |
9,380,000 |
91,210 |
|
-
Bristol Myers Squibb Q3 2021 Earnings Preview [10/26/2021 3:11 PM]
-
Bristol Myers Squibb EPS beats by $0.08, beats on revenue, boost guidance [10/27/2021 7:02 AM]
-
Bristol Myers Squibb posts Q3 earnings beat, FY forecast [10/27/2021 7:41 AM]
-
Bristol-Myers hits a 52-week low despite Q3 beat [10/27/2021 10:59 AM]
-
Hot Stocks: BMY sets low; SLAB hits new high; Solar stocks climb; CRTX plunges on clinical data; NRIX rises [10/27/2021 6:24 PM]
-
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS APPH, BMY, EAR INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits [Oct-26-21 03:50PM]
-
BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action Contact Lieff Cabraser [Oct-26-21 01:46PM]
-
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of APPH, BMY, EAR and HNST [Oct-26-21 10:37PM]
-
Bristol Myers Squibb Reports Third Quarter Financial Results for 2021 [Oct-27-21 06:59AM]
-
Bristol Myers reports 10% quarterly sales growth as cancer drugs rebound [Oct-27-21 06:59AM]
-
Bristol Myers Squibb says sales of Revlimid, Eliquis increased in the third quarter [Oct-27-21 07:49AM]
-
Bristol Myers Inches Up As Cancer Drugs Help Drive Narrow Quarterly Beat [Oct-27-21 09:02AM]
-
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates [Oct-27-21 08:15AM]
-
Earnings Data Deluge [Oct-27-21 09:53AM]
-
Bristol-Myers (BMY) Beats on Q3 Earnings & Sales, Tweaks View [Oct-27-21 09:24AM]
-
Bristol Myers Skids As Looming Generics Shadow Its Biggest Product [Oct-27-21 11:56AM]
-
Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More [Oct-27-21 11:10AM]
-
Q3 Earnings' Smooth Sailing Continues [Oct-27-21 10:27AM]
-
Bristol Myers Q3 Earnings In-line With Expectations, Raises Lower End Of FY21 Adjusted EPS Outlook [Oct-27-21 09:21AM]
-
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Oct-27-21 07:13PM]
|
28-07-2021 |
PM |
7:00 AM ET (Jul 28) |
BMY |
Bristol-Myers Squibb Company |
151,140 |
1.93 |
1.88 |
1.63 |
Bristol Myers Squibb EPS beats by $0.03, beats on revenue [7/28/2021 7:00 AM] |
68.73 |
1.24 (1.84%) |
68.73 |
0.0 (0.00%) |
56.75 - 68.99 |
10,394,788 |
8,430,000 |
14,383 |
|
-
Mizuho reiterates buy on BridgeBio following Bristol-Myers Squibb deal; sees 53% upside [7/27/2021 1:48 PM]
-
Bristol Myers Squibb Q2 2021 Earnings Preview [7/27/2021 12:39 PM]
-
Bristol Myers Squibb EPS beats by $0.03, beats on revenue [7/28/2021 7:00 AM]
-
Bristol Myers posts Q2 earnings beat on Opdivo Strength [7/28/2021 7:54 AM]
-
Top Analyst Reports for Comcast, Coca-Cola & Bristol-Myers Squibb [Jul-27-21 02:20PM]
-
Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY [Jul-27-21 11:14AM]
-
Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings [Jul-27-21 10:40AM]
-
Why Its Hard to Go Wrong With Bristol Myers Stock [Jul-27-21 06:00AM]
-
Bristol Myers sees return to growth for Opdivo, tops estimates [Jul-28-21 07:00AM]
-
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021 [Jul-28-21 06:59AM]
-
Bristol Myers swings to profit to beat second-quarter estimates as Opdivo returns to growth [Jul-28-21 07:12AM]
-
Bristol Myers Earnings Top Views; BMY Stock Just Below Buy Point [Jul-28-21 08:07AM]
-
Bristol Myers Posts Stronger-Than-Expected Earnings but Lowers Guidance [Jul-28-21 04:47AM]
-
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates [Jul-28-21 08:15AM]
-
Bristol Myers Squibb Stock Rises After Modest Earnings Beat [Jul-28-21 10:08AM]
-
Bristol Myers Q2 Earnings Slightly Ahead Of Estimates, Trims FY21 GAAP EPS Guidance [Jul-28-21 07:42AM]
-
Bristol Myers Retakes Buy Point After 'Solid' Quarter, Though Generics Loom [Jul-28-21 11:52AM]
-
Bristol-Myers Squibb (BMY) Q2 2021 Earnings Call Transcript [Jul-28-21 12:00PM]
-
Is BMY Stock A Buy After A Second-Quarter Beat As Revlimid Rivals Loom? [Jul-28-21 03:14PM]
-
Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow [Jul-28-21 01:57PM]
|
29-04-2021 |
PM |
7:00 AM ET (Apr 29) |
BMY |
Bristol-Myers Squibb Company |
147,190 |
1.74 |
1.83 |
1.72 |
Bristol Myers Squibb EPS misses by $0.07, misses on revenue [4/29/2021 7:04 AM] |
62.89 |
-3.14 (-4.76%) |
62.89 |
0.0 (0.00%) |
54.07 - 67.16 |
21,099,286 |
11,000,000 |
15,823 |
|
|
04-02-2021 |
PM |
7:00 AM ET (Feb 4) |
BMY |
Bristol-Myers Squibb Company |
142,230 |
1.46 |
1.37 |
1.22 |
Bristol Myers Squibb EPS beats by $0.04, beats on revenue [2/4/2021 7:02 AM] |
61.56 |
-0.29 (-0.76%) |
61.74 |
-0.29 (-0.47%) |
45.76 - 67.80 |
13,121,654 |
13,346,295 |
70,406 |
|
|
05-11-2020 |
PM |
7:00 AM ET (Nov 5) |
BMY |
Bristol-Myers Squibb Company |
138,030 |
1.63 |
1.49 |
1.17 |
Bristol Myers Squibb EPS beats by $0.14, beats on revenue [11/5/2020 7:01 AM] |
63.75 |
-1.68 (-2.57%) |
63.75 |
0.0 (0.00%) |
45.76 - 68.34 |
13,304,474 |
11,304,800 |
534,460 |
|
|
06-08-2020 |
PM |
7:00 AM ET (Aug 6) |
BMY |
Bristol-Myers Squibb Company |
133,720 |
1.63 |
1.43 |
1.18 |
Bristol Myers Squibb EPS beats by $0.16, beats on revenue [8/6/2020 7:01 AM] |
61.50 |
1.82 (3.04%) |
62.20 |
2.51 (4.21%) |
45.00 - 68.34 |
10,931,843 |
9,626,580 |
457,891 |
|
|